Date: 2017-07-26
Type of information: Company acquisition
Acquired company: Advinus Therapeutics (India)
Acquiring company: Eurofins Scientific (Luxembourg)
Amount: undisclosed
Terms:
- • On July 26, 2017, Eurofins Scientific announced that it has signed an exclusive agreement with Tata Group to acquire AdvinusTherapeutics, a leading preclinical and clinical phase contract research company for Safety Assessment, DMPK, CMC services, and Analytical R&D Services. The transaction is expected to close in the next few weeks, subject to the fulfilment of customary closing conditions.
- Advinus Therapeutics generated revenues of € 17 million in the Fiscal Year ending 31 March 2017 with over 300 staff.
Details:
- Advinus Therapeutics serves diverse industries such
as biotech, pharmaceuticals, biologics, agrochemicals, nutraceuticals and cosmetics. The company has submitted over 50 end-to-end investigational new drug applications to global regulators such as the FDA, the European Medicines
Agency (EMA), the Medicines and Healthcare products Regulatory Agency in the UK (MHRA) and Health Canada among others. Located in Bangalore, the company operates a stateof-the art 20,000 m2 facility on a large campus with ample space for expansion.
Advinus’ expertise complements Eurofins recent contract research, development and manufacturing (CDMO) capabilities following the acquisitions of Alphora in Canada and Amatsigroup in Europe. The company provides GMP testing and manufacturing capabilities, and is well positioned to capitalize on the growing R&D outsourcing market in the Asia-Pacific region.
Related: Technology - Services
Is general: Yes
